Markers of sympathetic nervous system activity associate with complex plasma lipids in metabolic syndrome subjects

Atherosclerosis

Volumn 256, Issue , 2017, Pages 21-28

  Nestel, Paul J ^a   Khan, Anmar A ^a,b,c   Straznicky, Nora E ^a   Mellett, Natalie A ^a   Jayawardana, Kaushala ^a   Mundra, Pyushkumar A ^a   Lambert, Gavin W ^a   Meikle, Peter J ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Insulin resistance; Lipidomics; Metabolic syndrome; NEFA; Norepinephrine; Sympathetic nervous system activity

Indexed keywords

CERAMIDE; CERAMIDE TRIHEXOSIDE; DIACYLGLYCEROL; FATTY ACID; GANGLIOSIDE GM3; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; NORADRENALIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; SPHINGOMYELIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; PHOSPHOLIPID; SPHINGOLIPID;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEUROTRANSMISSION; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; METABOLISM; OBESITY; PATHOPHYSIOLOGY; SYNAPTIC TRANSMISSION; TANDEM MASS SPECTROMETRY;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CERAMIDES; CROSS-SECTIONAL STUDIES; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NOREPINEPHRINE; OBESITY; PHOSPHOLIPIDS; SPHINGOLIPIDS; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION; TANDEM MASS SPECTROMETRY;

EID: 85004065368     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.11.032     Document Type: Article

References (41)

1. [1] Grassi, G., Dell'Oro, R., Quarti-Trevano, F., Scopeliti, F., Seravalle, G., Paleari, F., Gamba, P., Mancia, G., Neuroadrenergic and reflex abnormalities in patients with the metabolic syndrome. Diabetologia 48 (2005), 1359–1365.
2. [2] Mancia, G., Bousquet Elghozi, J.L., Esler, M., Grassi, G., Julius, S., Reid, J., Van Zwieten, P.A., The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 25 (2007), 909–920.
3. [3] Jamerson, K.A., Julius, S., Gudbrandsson, T., Andersson, O., Brant, D.O., Reflex sympathetic activation indices acute insulin resistance in the human forearm. Hypertension 21 (1993), 618–623.
4. [4] Straznicky, N.E., Lambert, E.A., Lambert, G.W., Masuo, K., Esler, M.D., Nestel, P.J., Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J. Clin. Endocrinol. Metab. 90 (2005), 5998–6005.
5. [5] Fagius, J., Ellerfelt, K., Lithell, H., Berne, C., Increase in muscle nerve sympathetic activity after glucose intake is blunted in the elderly. Clin. Auton. Res. 6 (1996), 195–203.
6. [6] Rowe, J.W., Young, J.B., Minaker, K.I., Stevens, A.L., Pallotta, J., Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30 (1981), 219–225.
7. [7] Sraznicky, N., Grima, M.T., Lambert, E.A., Sari, C.I., Eikelis, N., Nestel, P.J., Phillips, S.E., Hering, D., Karapanagiotidis Dixon, J.B., Schlaich, M.P., Lambert, G.W., Arterial norepinephrine concentration is inversely and independently associated with insulin clearance in obese individuals with metabolic syndrome. J. Clin. Endocrinol. Metab. 90 (2015), 5998–6005.
8. [8] Straznicky, N., Lambert, E.A., Nestel, P.J., McGrane, M., Dalwood, T., Schlaich, M., Matsuo, K., Eikelis, N., de Courten, B., Esler, M.D., Socratous, F., Chopra, R., Ika Sari, C., Paul, E., Lambert, G., Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome patients. Diabetes 59 (2010), 71–79.
9. [9] Straznicky, N., Lambert, E.A., Grima, M.T., Eikelis, N., Richards, K., Nestel, P.J., Dawood, T., Masuo, K., Sari, C.I., Dixon, J.B., Esler, M.D., Paul, E., Schlaich, M.P., Lambert, G.W., The effect of weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia. Obesity 22 (2014), 652–662.
10. [10] Haus, J.M., Kashyap, S.R., Kasumov, T., Zhang, R., Kelly, K.R., Defronzo, R.A., Kirwan, J.P., Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with severity of insulin resistance. Diabetes 58 (2009), 337–343.
11. [11] de Mello, V.D., Lankinen, M., Schwab, U., Kolehmainen, M., Lehto, S., Seppanen-Laakso, T., Oresic, M., Pulkkinen, L., Uusitupa, M., Erkkila, A.T., Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52 (2009), 2612–2615.
12. [12] Larsen, P.J., Tennagels, N., On ceramides, other sphingolipids and impaired glucose homeostasis. Mol. Metab. 3 (2014;June), 252–260.
13. [13] Zeghari, N., Younsi, M., Meyer, L., Donner, M., Drouin, P., Ziegler, O., Adipocyte and erythrocyte plasma membrane phospholipid composition and hyperinsulinemia: a study in nondiabetic and diabetic obese women. Int. J. Obes. Relat. Metab. Disord. 24 (2000), 1600–1607.
14. [14] Barber, M.N., Ross, S., Yang, C., Meikle, P.J., Staples, M., Febraio, M., Bruce, C.R., Waki, H., Plasma lysophosphatidylcholines are reduced in obesity and type 2 diabetes. PLoS One, 7, 2012, e41456.
15. [15] Meikle, P.J., Wong, G., Barlow, C.K., Weir, J.M., Greeva, M.A., MacIntosh, G.L., Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One, 8, 2013, e74341.
16. [16] De Chaves, E.P., Sipione, S., Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS 584 (2010), 1748–1759.
17. [17] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Diagnosis and management of the metabolic syndrome: an american heart association, national heart lung & blood institute scientific statement. Circulation 112 (2005), 2735–2752.
18. [18] Matthews, D.R., Hosker, J.P., Rudneski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
19. [19] Matsuda, M., DeFronzo, R.A., Insulin sensitivity studies obtained from oral glucose tolerance testing: comparison with euglycemic insulin clamp. Diabetes Care 22 (1999), 1462–1470.
20. [20] Meikle, P., Wong, G., Tsorotes, D., Barlow, C.K., Weir, J.M., Christopher, M.J., MacIntosh, G.L., Goudy, B., Stern, L., Kowalczyk, A., Haviv, I., White, A.J., Dart, A.M., Duffy, S.J., Jennings, G.L., Kingwell, B.A., Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 2723–2732.
21. [21] Fiorian JP, Pawelczyk AS. Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans. Clin Sci 2910;118:61–69.
22. [22] Nestel, P.J., Plasma triglyceride concentration and plasma free fatty acid changes in response to norepinephrine in man. J. Clin. Invest. 43 (1964), 77–82.
23. [23] Steinberg, D., Nestel, P.J., Buskirk, E.R., Thompson, R.H., Calorigenic effect of norepinephrine correlated with plasma free fatty acid turnover and oxidation. J. Clin. Invest. 43 (1964), 167–176.
24. [24] Straznicky, N., Lambert, G.W., McGrane, M.T., Masuo, K., Dawood, T., Nestel, P.J., Eikelis, N., Schlaich, M.P., Esler, M.D., Socratous, F., Chpra, R., Lambert, E.A., Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes 58 (2009), 1126–1132.
25. [25] Vaz, M., Jennings, G.L., Turner, A., Cox, H., Lambert, G., Esler, M., Regional sympathetic nervous system activity and oxygen consumption in obese normotensive human subjects. Circulation 96 (1997), 3423–3429.
26. [26] Rogowski, O., Steinvil, A., Berliner, S., Cohen, M., Ben-Bassat, O.K., Shapira, I., Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc. Diabetol. 8 (2009), 55–58.
27. [27] Jiang, X., Liu, X., Wu, S., Zhang, G.Q., Peng M,Wu, Y., Zheng, X., Ruan, C., Zhang, W., Metabolic syndrome is associated with and predicted by resting heart rate: a cross-sectional and longitudinal study. Heart 101 (2015), 44–49.
28. [28] Candiloros, H., Zeghari, N., Ziegler, O., Donner, M., Drouin, P., Hyperinsulinemia is related to erythrocyte phospholipid composition and membrane fluidity changes in obese nondiabetic women. J. Clin. Endocrinol. Metab. 81 (1996), 2912–2918.
29. [29] Starznicky, N.E., Eikelis, N., Lambert, E.A., Esler, M.D., Mediators of sympathetic activation in metabolic syndrome obesity. Curr. Hypertens. Rep. 10 (2008), 440–447.
30. [30] Straznicky, N.E., Grima, M.T., Sari, C.I., Eikelis, N., Lambert, E.A., Nestel, P.J., Esler, M.D., Dixon, J.B., Chopra, R., Tilbrook, A.J., Schlaich, M.P., Lambert, G.W., Neuroadrenergic dysfunction along the diabetic continuum. Diabetes 61 (2012), 1–11.
31. [31] Nestel, P.J., Straznicky, N., Mellett, N.A., Wong, G., De Souza, D.P., Tull, D.L., Barlow, C.K., Grima, M.T., Meikle, P.J., Specific plasma lipid classes and phospholipid fatty acids indicative of diary food consumption associate with insulin sensitivity. Am. J. Clin. Nutr. 99 (2014), 1–8.
32. [32] Yea, K., Kim, J., Yoon, J.H., Kwon, T., Kim, J.H., Lee, B.D., Lee, H.-J., Lee, S.J., Kim, J.-I., Lee, T.G., Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J. Biol. Chem. 284 (2009), 33833–33840.
33. [33] Long, S.D., Pekala, P.H., Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem. J. 319 (1996), 179–184.
34. [34] Yamashita, T., Hashiramoto, A., Haluzik, M., Mizukami, H., Beck, S., Norton, A., Kono, M., Tsuji, S., Daniotti, J.L., Werth, N., Sandhoff, R., Sandhoff, K., Proia, R.L., Enhanced insulin sensitivity in mice lacking ganglioside GM3. PNAS 100 (2003), 3445–3449.
35. [35] Cheng, J.M., Suoniemi, M., Kardys, I., Vihervara, T., de Boer, S.P.M., Akkerhuis, M., Sysy-Aho, M., Ekroos, K., Garcia-Garcia, H.M., Rohit, M., Oemrawsingh, M., Regar, E., Koenig, W., Serruys, P.W., van Geuns, R.-J., Boersma, E., Laaksonen, R., Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis 243 (2015), 560–566.
36. [36] Sutter, I., Velagapudi, A.O., Riwanto, M., Manz, J., Rohrer, L., Rentsch, K., Homemann, T., Landmesser, U., von Eckardstein, A., Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis 241 (2015), 539–548.
37. [37] Yetukuri, L., Soderlund, S., Koivuniemi, Seppanen-Lakso T., Niemela, P.S., Hyvonen, M., Taskinen, M.-R., Vattulainen, I., Jauhinainen, M., Oresie, M., Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J. Lipid Res. 51 (2010), 2341–2351.
38. [38] Stahlman, M., Fagerberg, B., Adiels, M., Ekroos, K., Chapman, J.M., Kontush, A., Boren, J., Dyslipidemia, but not hyperglycemia and insulin resistance is associated with marked alterations in HDL lipidome in type 2 diabetic subjects in DIWA cohort: impact on small HDL particles. Biochim. Byophys Acta 1831 (2013), 1609–1617.
39. [39] Jiang, X.-C., Paultre, F., Pearson, T.A., Reed RC,Francis, C.K., Berglund, L., Tall, A.R., Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 2614–2618.
40. [40] Stegemann, M., Pechlaner, R., Willeit, P., Langley, S.R., Mangino, M., Mayr, U., Menni, C., Moayyeri, A., Santer, P., Ruegger, G., Lipidomic profiling and risk of cardiovascular disease in the prospective population based Brunneck study. Circulation 129 (2014), 1821–1831.
41. [41] Shamim, H., Masataka, I., Toshihiko, K., Role of ceramides in the physiology and pathophysiology of nervous system. Adv. Neuroimmune Biol. 4 (2013), 35–44.